MA49971A - Vésicules extracellulaires modifiées et leurs utilisations - Google Patents
Vésicules extracellulaires modifiées et leurs utilisationsInfo
- Publication number
- MA49971A MA49971A MA049971A MA49971A MA49971A MA 49971 A MA49971 A MA 49971A MA 049971 A MA049971 A MA 049971A MA 49971 A MA49971 A MA 49971A MA 49971 A MA49971 A MA 49971A
- Authority
- MA
- Morocco
- Prior art keywords
- extracellular vesicles
- modified extracellular
- modified
- vesicles
- extracellular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962835430P | 2019-04-17 | 2019-04-17 | |
PCT/US2019/033629 WO2020101740A1 (fr) | 2018-11-16 | 2019-05-22 | Vésicules extracellulaires modifiées et leurs utilisations |
Publications (2)
Publication Number | Publication Date |
---|---|
MA49971A true MA49971A (fr) | 2020-07-01 |
MA49971B1 MA49971B1 (fr) | 2022-01-31 |
Family
ID=70732111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA49971A MA49971B1 (fr) | 2019-04-17 | 2019-05-22 | Vésicules extracellulaires modifiées et leurs utilisations |
Country Status (27)
Country | Link |
---|---|
EP (2) | EP4059510A1 (fr) |
JP (2) | JP7538795B2 (fr) |
KR (1) | KR20210098473A (fr) |
CN (1) | CN113286603A (fr) |
AU (1) | AU2019378591A1 (fr) |
BR (1) | BR112021009231A2 (fr) |
CA (1) | CA3119720A1 (fr) |
CL (1) | CL2021001278A1 (fr) |
CY (1) | CY1124897T1 (fr) |
DK (1) | DK3672614T3 (fr) |
EA (1) | EA202191334A1 (fr) |
ES (1) | ES2907967T3 (fr) |
HR (1) | HRP20220020T1 (fr) |
HU (1) | HUE057300T2 (fr) |
IL (1) | IL283167A (fr) |
LT (1) | LT3672614T (fr) |
MA (1) | MA49971B1 (fr) |
MD (1) | MD3672614T2 (fr) |
MX (1) | MX2021005636A (fr) |
PH (1) | PH12021551088A1 (fr) |
PL (1) | PL3672614T3 (fr) |
PT (1) | PT3672614T (fr) |
RS (1) | RS62863B1 (fr) |
SG (1) | SG11202104956QA (fr) |
SI (1) | SI3672614T1 (fr) |
TW (1) | TWI846697B (fr) |
WO (1) | WO2020101740A1 (fr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022531095A (ja) * | 2019-04-17 | 2022-07-06 | コディアック バイオサイエンシーズ, インコーポレイテッド | エキソソーム及びaavの組成物 |
EP3994158A1 (fr) | 2019-07-03 | 2022-05-11 | Codiak BioSciences, Inc. | Vésicules extracellulaires ciblant des lymphocytes t et leurs utilisations |
CN114641570A (zh) | 2019-08-14 | 2022-06-17 | 科迪亚克生物科学公司 | 具有靶向kras的反义寡核苷酸的细胞外囊泡 |
WO2021030769A1 (fr) | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Vésicules extracellulaires avec des oligonucléotides antisens de nras |
JP2022544289A (ja) * | 2019-08-14 | 2022-10-17 | コディアック バイオサイエンシーズ, インコーポレイテッド | Stat6を標的とする細胞外小胞-aso構築物 |
EP4013878A1 (fr) | 2019-08-14 | 2022-06-22 | Codiak BioSciences, Inc. | Constructions vésicule extracellulaire-oligonucléotide antisens (aso) ciblant cebp/bêta |
EP4034150A1 (fr) | 2019-09-25 | 2022-08-03 | Codiak BioSciences, Inc. | Agoniste de sting comprenant des exosomes combinés à l'il-12 présentant des exosomes pour le traitement d'une tumeur |
WO2021062058A1 (fr) | 2019-09-25 | 2021-04-01 | Codiak Biosciences, Inc. | Agoniste de sting comprenant des exosomes pour le traitement de troubles neuro-immunologiques |
WO2021062057A1 (fr) | 2019-09-25 | 2021-04-01 | Codiak Biosciences, Inc. | Chargement exogène d'exosomes par lyophilisation |
CN114727947A (zh) | 2019-09-25 | 2022-07-08 | 科迪亚克生物科学公司 | 细胞外囊泡组合物 |
EP4034276A1 (fr) | 2019-09-25 | 2022-08-03 | Codiak BioSciences, Inc. | Procédés de production de vésicules extracellulaires |
CN115484990A (zh) | 2020-03-12 | 2022-12-16 | 基础科学研究院 | 诱导具有基因组序列变异的细胞凋亡的组合物及使用组合物诱导细胞凋亡的方法 |
WO2021184020A1 (fr) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Méthodes de traitement d'une neuro-inflammation |
WO2021184017A1 (fr) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Vésicules extracellulaires pour le traitement de troubles neurologiques |
WO2021184021A1 (fr) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Constructions de vésicules extracellulaires - aso ciblant pmp22 |
WO2021189047A2 (fr) | 2020-03-20 | 2021-09-23 | Codiak Biosciences, Inc. | Vésicules extracellulaires pour thérapie |
US20230220068A1 (en) | 2020-06-05 | 2023-07-13 | Codiak Biosciences, Inc. | Anti-transferrin extracellular vesicles |
JP2023537070A (ja) * | 2020-08-07 | 2023-08-30 | アミカス セラピューティックス インコーポレイテッド | 小胞を標的とするタンパク質及びその使用 |
WO2022066883A1 (fr) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Vésicules extracellulaires comprenant des antigènes kras et leurs utilisations |
EP4217087A2 (fr) | 2020-09-23 | 2023-08-02 | Codiak BioSciences, Inc. | Procédé de préparation de vésicules extracellulaires |
US20240241020A1 (en) | 2020-09-23 | 2024-07-18 | Lonza Sales Ag | Process for preparing extracellular vesicles |
GB202015399D0 (en) * | 2020-09-29 | 2020-11-11 | Evox Therapeutics Ltd | Engineered extracellular vesicles displaying enhanced pharmacokinetics |
WO2022076596A1 (fr) | 2020-10-06 | 2022-04-14 | Codiak Biosciences, Inc. | Constructions vésicules extracellulaires-oas ciblant stat6 |
CN112410304A (zh) * | 2020-11-12 | 2021-02-26 | 天津大学 | 一种基因修饰的外泌体及其制备方法和应用 |
CN112899307A (zh) * | 2021-01-28 | 2021-06-04 | 苏州大学 | GluN1和/或GluN2亚基羧基末端豆蔻酰化的NMDA受体的应用 |
IL305172A (en) | 2021-02-17 | 2023-10-01 | Lonza Sales Ag | Methods for loading extracellular vesicles |
KR20230147125A (ko) * | 2021-02-17 | 2023-10-20 | 론자 세일즈 아게 | 세포외 소포-nlrp3 길항제 |
EP4304566A1 (fr) | 2021-04-01 | 2024-01-17 | Lonza Sales AG | Compositions de vésicules extracellulaires |
CN114057893B (zh) * | 2021-04-26 | 2022-12-30 | 苏州大学 | 一种编码线粒体定位的豆蔻酰化多肽及其制备方法与应用 |
CN117126886A (zh) * | 2022-05-20 | 2023-11-28 | 谛邈生物科技(北京)有限公司 | 一种实现工程化EVs功能蛋白模块化装载的核酸构建体及其应用 |
WO2023229366A1 (fr) * | 2022-05-24 | 2023-11-30 | Shiftbio Co., Ltd. | Vésicules extracellulaires modifiées en surface et leurs utilisations thérapeutiques |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
PT2254586E (pt) * | 2008-02-22 | 2015-05-18 | Agency Science Tech & Res | Partículas de células estaminais mesenquimais |
FR2950350B1 (fr) | 2009-09-24 | 2013-12-13 | Centre Nat Rech Scient | Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations |
EP3164420A4 (fr) * | 2014-06-30 | 2018-05-23 | Tarveda Therapeutics, Inc. | Conjugués ciblés, particules et préparations associées |
WO2016138525A1 (fr) * | 2015-02-27 | 2016-09-01 | University Of Washington | Ensembles polypeptidiques et procédés de production associés |
US20190008902A1 (en) * | 2015-12-30 | 2019-01-10 | The Regents Of The University Of California | Methods for enhanced production and isolation of cell-derived vesicles |
US10617768B2 (en) * | 2016-07-12 | 2020-04-14 | Santa Clara University | Engineered exosomes for the delivery of bioactive cargo using transmembrane tetraspanins |
WO2018039119A1 (fr) * | 2016-08-22 | 2018-03-01 | Codiak Biosciences, Inc. | Procédés de suppression de l'administration d'exosomes vers le foie et la rate |
US20200025685A1 (en) * | 2016-12-15 | 2020-01-23 | Codiak Biosciences, Inc. | Methods of measuring exosomes using intrinsic fluorescence |
SG11202001008RA (en) | 2017-08-25 | 2020-03-30 | Codiak Biosciences Inc | Preparation of therapeutic exosomes using membrane proteins |
WO2019099942A1 (fr) * | 2017-11-17 | 2019-05-23 | Codiak Biosciences, Inc. | Compositions d'exosomes modifiés et procédés de chargement de charges d'exosomes luminaux |
US20230181758A1 (en) * | 2019-07-03 | 2023-06-15 | Codiak Biosciences, Inc. | Extracellular vesicles targeting dendritic cells and uses thereof |
-
2019
- 2019-05-22 CA CA3119720A patent/CA3119720A1/fr active Pending
- 2019-05-22 SG SG11202104956QA patent/SG11202104956QA/en unknown
- 2019-05-22 HU HUE19731027A patent/HUE057300T2/hu unknown
- 2019-05-22 MA MA49971A patent/MA49971B1/fr unknown
- 2019-05-22 EP EP21200884.1A patent/EP4059510A1/fr active Pending
- 2019-05-22 JP JP2021526563A patent/JP7538795B2/ja active Active
- 2019-05-22 ES ES19731027T patent/ES2907967T3/es active Active
- 2019-05-22 PL PL19731027T patent/PL3672614T3/pl unknown
- 2019-05-22 AU AU2019378591A patent/AU2019378591A1/en active Pending
- 2019-05-22 KR KR1020217018358A patent/KR20210098473A/ko active Search and Examination
- 2019-05-22 SI SI201930182T patent/SI3672614T1/sl unknown
- 2019-05-22 WO PCT/US2019/033629 patent/WO2020101740A1/fr unknown
- 2019-05-22 EP EP19731027.9A patent/EP3672614B1/fr active Active
- 2019-05-22 MX MX2021005636A patent/MX2021005636A/es unknown
- 2019-05-22 PT PT197310279T patent/PT3672614T/pt unknown
- 2019-05-22 BR BR112021009231-5A patent/BR112021009231A2/pt unknown
- 2019-05-22 DK DK19731027.9T patent/DK3672614T3/da active
- 2019-05-22 MD MDE20200694T patent/MD3672614T2/ro unknown
- 2019-05-22 HR HRP20220020TT patent/HRP20220020T1/hr unknown
- 2019-05-22 CN CN201980083366.0A patent/CN113286603A/zh active Pending
- 2019-05-22 LT LTEPPCT/US2019/033629T patent/LT3672614T/lt unknown
- 2019-05-22 RS RS20220009A patent/RS62863B1/sr unknown
- 2019-05-22 EA EA202191334A patent/EA202191334A1/ru unknown
- 2019-05-23 TW TW108117910A patent/TWI846697B/zh active
-
2021
- 2021-05-11 PH PH12021551088A patent/PH12021551088A1/en unknown
- 2021-05-13 IL IL283167A patent/IL283167A/en unknown
- 2021-05-14 CL CL2021001278A patent/CL2021001278A1/es unknown
-
2022
- 2022-01-07 CY CY20221100020T patent/CY1124897T1/el unknown
-
2024
- 2024-05-10 JP JP2024077013A patent/JP2024097929A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
HUE057300T2 (hu) | 2022-05-28 |
SG11202104956QA (en) | 2021-06-29 |
IL283167A (en) | 2021-06-30 |
CY1124897T1 (el) | 2023-01-05 |
WO2020101740A1 (fr) | 2020-05-22 |
SI3672614T1 (sl) | 2022-04-29 |
CN113286603A (zh) | 2021-08-20 |
JP7538795B2 (ja) | 2024-08-22 |
CL2021001278A1 (es) | 2022-03-11 |
CA3119720A1 (fr) | 2020-05-22 |
KR20210098473A (ko) | 2021-08-10 |
MA49971B1 (fr) | 2022-01-31 |
PH12021551088A1 (en) | 2022-01-03 |
JP2024097929A (ja) | 2024-07-19 |
TW202038993A (zh) | 2020-11-01 |
RS62863B1 (sr) | 2022-02-28 |
JP2022513049A (ja) | 2022-02-07 |
BR112021009231A2 (pt) | 2021-08-10 |
EP3672614B1 (fr) | 2021-10-06 |
HRP20220020T1 (hr) | 2022-04-01 |
EP4059510A1 (fr) | 2022-09-21 |
AU2019378591A1 (en) | 2021-06-17 |
MX2021005636A (es) | 2021-07-06 |
PL3672614T3 (pl) | 2022-03-07 |
MD3672614T2 (ro) | 2022-04-30 |
DK3672614T3 (da) | 2022-01-10 |
ES2907967T3 (es) | 2022-04-27 |
PT3672614T (pt) | 2022-02-11 |
TWI846697B (zh) | 2024-07-01 |
EA202191334A1 (ru) | 2022-02-10 |
LT3672614T (lt) | 2022-04-11 |
WO2020101740A9 (fr) | 2021-06-10 |
EP3672614A1 (fr) | 2020-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49971A (fr) | Vésicules extracellulaires modifiées et leurs utilisations | |
MA50618A (fr) | Polyrhérapies et leurs utilisations | |
FR24C1023I1 (fr) | Anticorps thérapeutiques et leurs utilisations | |
MA51288A (fr) | Analogues d'incrétine et leurs utilisations | |
MA46708A (fr) | Anticorps anti-pd1 et leurs utilisations | |
MA51287A (fr) | Analogues d'incrétine et leurs utilisations | |
MA55627A (fr) | Agonistes de glp-1r et leurs utilisations | |
MA47789A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
MA50256A (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
MA49683A (fr) | Anticorps anti-cd8 et leurs utilisations | |
MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
MA55083A (fr) | Polyribonucléotides et leurs utilisations cosmétiques | |
MA49687A (fr) | Anticorps anti-ctla-4 et leurs utilisations | |
MA52949A (fr) | Anticorps anti-pd-1 et leurs utilisations | |
MA55565A (fr) | Agents de dégradation de stat et leurs utilisations | |
MA42622A (fr) | Agents de liaison à tigit et leurs utilisations | |
MA50397A (fr) | Anticorps anti-tau et leurs utilisations | |
MA46990A (fr) | Compositions de glp-1 et leurs utilisations | |
MA50265A (fr) | Conjugués anticorps-récepteur alpha anti-folate et leurs utilisations | |
MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
MA53184A (fr) | Anticorps anti-ox40 et leurs utilisations | |
MA49886A (fr) | Anticorps anti-par2 et leurs utilisations | |
MA41460A (fr) | Agents de liaison à la tnfrsf et leurs utilisations | |
MA45943A (fr) | Compositions ignifuges et leurs utilisations | |
MA46704A (fr) | Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations |